A 10-week Efficacy Study of NOE-105 in Childhood Onset Fluency Disorder (Orpheus)

NCT05583955 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

75

Enrollment

INDUSTRY

Sponsor class

Conditions

Childhood-Onset Fluency Disorder

Interventions

DRUG: NOE-105
DRUG: Placebo

Sponsor

Noema Pharma AG